Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Metropolis Healthcare reported strong consolidated revenue of ₹42,919 lakhs for Q2 FY26, up about 23% from ₹34,979 lakhs in Q2 FY25, driven by business acquisitions and organic growth. Profit after tax rose to ₹5,289 lakhs from ₹4,670 lakhs (up ~13% YoY). On a standalone basis, revenue grew ~11% to ₹35,571 lakhs and PAT rose ~10% to ₹4,663 lakhs. The Board declared an interim dividend of ₹4 per share (200% on face value of ₹2), with record date November 11, 2025. The company completed three pathology business acquisitions during the year (DAPIC, Scientific Metropolis, Ambika Pathology) totaling roughly ₹12,361 lakhs in consideration. Auditor BSR & Co. LLP issued an unmodified (clean) limited review report. On the tax front, the disputed income tax demand of ₹7,306 lakhs has been reduced to ₹3,880 lakhs with favorable appellate orders for 6 years.
Strong consolidated top-line growth and continued dividend payouts signal healthy operational momentum, though standalone growth is more modest. Clean auditor opinion and progress on tax disputes are positive for shareholders. Expect near-term stock reaction to be neutral-to-positive given steady growth and consistent dividend.